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Spontaneous intracranial hemorrhage is a debilitating form of stroke, often leading to death or permanent
cognitive impairment. Many of the causative genes and the underlying mechanisms implicated in
developmental cerebral-vascular malformations are unknown. Recent in vitro and in vivo studies in mice
have shown inhibition of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway to be
effective in stabilizing cranial vessels. Using a combination of pharmacological and genetic approaches
to speciﬁcally inhibit the HMGCR pathway in zebraﬁsh (Danio rerio), we demonstrate a requirement for
this metabolic pathway in developmental vascular stability. Here we report that inhibition of HMGCR
function perturbs cerebral-vascular stability, resulting in progressive dilation of blood vessels, followed
by vessel rupture, mimicking cerebral cavernous malformation (CCM)-like lesions in humans and murine
models. The hemorrhages in the brain are rescued by prior exogenous supplementation with geranylgeranyl
pyrophosphate (GGPP), a 20-carbon metabolite of the HMGCR pathway, required for the membrane
localization and activation of Rho GTPases. Consistent with this observation, morpholino-induced
depletion of the b-subunit of geranylgeranyltransferase I (GGTase I), an enzyme that facilitates the
post-translational transfer of the GGPP moiety to the C-terminus of Rho family of GTPases, mimics the
cerebral hemorrhaging induced by the pharmacological and genetic ablation of HMGCR. In embryos with
cerebral hemorrhage, the endothelial-speciﬁc expression of cdc42, a Rho GTPase involved in the
regulation of vascular permeability, was signiﬁcantly reduced. Taken together, our data reveal a metabolic
contribution to the stabilization of nascent cranial vessels, requiring protein geranylgeranylation acting
downstream of the HMGCR pathway.
& 2012 Elsevier Inc. All rights reserved.Introduction
HMGCR catalyzes the rate-limiting step in the conversion of
HMGCoA to mevalonate, giving rise to mevalonate-derived mole-
cules including cholesterol and isoprenoids (Goldstein and Brown,
1990). A complex feedback mechanism involving both steroidal and
non-steroidal mediated pathways is involved in the regulation and
maintenance of HMGCR activity (Brown and Goldstein, 1997;
Nakanishi et al., 1988, Omkumar et al., 1994; DeBose-Boyd, 2008).
Statins, competitive inhibitors of HMGCR, are pharmaceuticals that
bind part of the HMG-binding residues of the enzyme and inhibit its
activity (Istvan and Deisenhofer, 2001). In addition to lowering
cholesterol levels, statins also curtail the biosynthesis of other
lipids, namely isoprenoids, which otherwise serve as essential lipid
attachments for the Rho family of GTPases (Bishop and Hall, 2000).
Hence, an efﬁcient way to elucidate HMGCR gene function duringll rights reserved.
rio, Canada K1N 6N5.development is to use statins for which the biochemical mode of
action is well characterized. Deﬁciencies in HMGCR activity during
development are implicated in prenylation-dependent germ cell
migration delay and misguidance in both Drosophila and zebraﬁsh
(Danio rerio) models (Santos and Lehmann, 2004; Thorpe et al.,
2004). A point mutation identiﬁed at position 1575 of hmgcrb, the
maternally-expressed hmgcr paralog in zebraﬁsh, results in defec-
tive heart-tube formation due to impaired post-translational pre-
nylation of small GTPases (D’amico et al., 2007). In contrast,
targeted disruption of hmgcr in mice results in early embryonic
lethality, which is indicative of the crucial function that HMGCR-
mediated metabolism and downstream signalling events play
during mammalian development (Ohashi et al., 2003). Presently,
the developmental processes that require adequate HMGCR func-
tion remains poorly understood.
Pharmacological inhibition of the HMGCR pathway was shown to
exert both angiostatic and angiogenic effects in vitro (Lu et al., 2004;
Khaidakov et al., 2009; Weis et al., 2002; Kaneta et al., 2003; Li et al.,
2002; Acquavella et al., 2009). An outstanding question is whether
perturbations of the HMGCR pathway would disrupt the stabilization
of nascent vessels and overall vascular morphogenesis in vivo, and,
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ference with these processes during a period of rapid angiogenesis.
Zebraﬁsh have recently been utilized as a suitable model to dissect
the etiology of cerebral cavernous malformation (CCM) (Kleaveland
et al., 2009; Hogan et al., 2008; Yoruk et al., 2012). Moreover, recent
work in zebraﬁsh demonstrates that proteins involved in the activa-
tion and transduction of Rho GTPase-mediated signalling pathways
synergistically participate in the development of the vascular network
in zebraﬁsh. Deﬁciencies within this pathway impair the stabilization
and maturation of nascent vessels by preventing the association of
mural cells with endothelial cells, giving rise to multiple hemorrhages
in the brain (Buchner et al., 2007; Liu et al., 2007), along with more
pronounced defects in vascular morphogenesis (Epting et al., 2010).
It is known that the mevalonate-derived metabolite, geranylgeranyl-
pyrophosphate (GGPP) serves as an end-product for the lipidation
and subcellular localization of Rho GTPases to the plasma membrane,
which is critical for their activation and function (Bishop and Hall,
2000). Hence, depleted GGPP levels reduce the GTP-binding capacity
of Rho GTPases, rendering them cytosolic and inactive. Although the
Rho GTPase pathway has been implicated in CCM pathology, there is
discrepancy between the mechanisms in mouse and zebraﬁsh. More
speciﬁcally, studies in mice show that global inhibition of Rho GTPase
prenylation via statin-mediated blockage of the HMGCR pathway
restores endothelial barrier integrity, thus reversing the vascular
permeability dysfunction in mice that are genetically predisposed
for CCM (Whitehead et al., 2009). Consistent with this observation,
transcript levels of the Rho GTPases, RhoA, Rac and cdc42, were
signiﬁcantly elevated in lesions of a mousemodel of CCM (Louvi et al.,
2011). Hence, in mice, statin-mediated inhibition of Rho GTPase
signalling, through decreased GGPP biosynthesis, is reported to be
an effective treatment to attenuate vascular permeability (Li and
Whitehead, 2010), whereas in zebraﬁsh, mutation and morpholino
induced loss of function of proteins that participate in the activation
and transduction of Rho GTPase signalling promotes vascular perme-
ability (Buchner et al., 2007; Liu et al., 2007).
To further investigate this discrepancy, we used two structurally
different statin molecules and two morpholino oligonucleotides with
non-overlapping sequences to inhibit zebraﬁsh HMGCR function, all
of which resulted in grossly dilated vessels, followed by progressive
loss of vascular stability in the brain at speciﬁc developmental stages
during which nascent cranial vessels are more prone to rupture. Prior
supplementation with exogenous mevalonate or GGPP, two of the
metabolites downstream of the HMGCR pathway, rescued the cere-
bral hemorrhage phenotype. Furthermore, morpholino-mediated
speciﬁc disruption of the GGTase I-mediated prenylation pathway
also mimicked the cerebral hemorrhages attributed to the inhibition
of the HMGCR pathway. Interestingly, in embryos with cerebral
hemorrhage, the vascular-speciﬁc expression of cdc42, a Rho GTPase
implicated in the mediation of endothelial barrier function (Kouklis
et al., 2003; Broman et al., 2006; Ramchandran et al., 2008; Spindler
et al., 2010) and highly enriched on the vacuole membranes (Eitzen
et al., 2001; Isgandarova et al., 2007), was noticeably reduced in the
head and trunk vasculature, as early as 24 hpf. Our results highlight
a requirement for HMGCR metabolism, through GGPP biosynthesis,
to the establishment of cerebral-vascular stability during zebraﬁsh
development, likely mediated by CAAX proteins that require gera-
nylgeranylation for their activation.Materials and methods
Zebraﬁsh husbandry and transgenic lines
Adult zebraﬁsh were maintained under a constant temperature
of 28 1C and a 14 h light: 10 h dark photoperiod in the University of
Ottawa Aquatic Care Facility. Embryos were obtained throughnatural breeding of adult zebraﬁsh and were kept at 28.5 1C in
embryo medium (5 mmol/L NaCl, 0.17 mmol/L KCl, 0.33 mmol/L
CaCl2, 0.33 mmol/L MgSO4). The double transgenic Tg(ﬂi1:EGFP);
(gata-1:DsRed) zebraﬁsh line was kindly provided by Dr. Beth
Roman (University of Pittsburgh, Pennsylvania). The Tg(ﬂi1:EGFP-
cdc42wt)y48 was kindly provided by Dr. Brant Weinstein (National
Institute of Child Health and Human Development, Maryland). All
experiments were carried out in accordance with a protocol
approved by the University of Ottawa Protocol Review Committee
and conform to the published guidelines of the Canadian Council
on Animal Care for the use of animals in research and teaching.
Drug treatment and metabolite rescue experiments
For pharmacological inhibition of HMGCR, zebraﬁsh embryos
(1–2 hours post fertilization; hpf) were treated with Atorvastatin
(ATV; Pﬁzer Inc., Connecticut USA) or Cerivastatin (CVT; Sequoia
Research Products Ltd. Pangbourne, UK) in a single-exposure manner
in embryo medium. ATV was dissolved in DMSO, whereas CVT was
dissolved in sterile/distilled water. All solutions were aliquoted and
kept at 20 1C until used. Embryos for the dose-response experi-
ments were placed in ﬁnal concentrations of 0.3, 0.5 or 1 mg/L ATV;
CVT was administered at 0.15 mg/L. For mevalonate rescue experi-
ments, similar numbers of embryos were placed in embryo medium
containing 0.5 mg/L ATV and 1, 1.6, 3.2 or 4.4 mmol/L mevalonic acid
(Sigma-Aldrich) or DMSO as vehicle control. Each treatment group
consisted of more than 70 embryos and all exposure experiments
were repeated at least 8 times. GGPP rescue experiments were
performed by administering 0.5 mg/L ATV and 0.5, 2 or 4 mg/L GGPP
(Sigma-Aldrich) dissolved in DMSO/methanol or DMSO/methanol, as
vehicle control.
Whole-mount o-Dianisidine (OD) staining and cryosectioning
Zebraﬁsh embryos at various developmental stages were ﬁxed
in 4% PFA/1X Phosphate Buffered Saline Tween-20 (PBST) overnight
and subsequently stained for hemoglobin using o-Dianisidine, a
sensitive marker of hemoglobin. Brieﬂy, unﬁxed embryos were
dechorionated and stained with a solution of OD (0.6 mg/mL)
(Sigma-Aldrich) containing 0.01 M sodium acetate (pH 4.5), 0.65%
hydrogen peroxide, and 40% (v/v) ethanol in the dark for 15 min.
Treated embryos were visualized using a Nikon NBZ 1500 dissect-
ing microscope with a Nikon DXM 1200 C digital camera and stored
in 50% glycerol at 4 1C. For cryosectioning, whole-mount embryos
previously stained with OD were equilibrated to 30% sucrose/1X
PBST overnight. The next day, the samples were mounted in tissue
freezing medium (Triangle Biomedical Sciences). Transverse sec-
tions of 10 mm thickness were cut on a Leica CM1850 standard
cryostat (Leica Microsystems) at 20 1C.
Confocal microscopy
For confocal microscopy, 48–52 hpf Tg(ﬂk1:EGFP;gata1:dsRED)
embryos previously treated with ATV or DMSO were embedded in
1% low melting agarose in embryo medium and tricaine mesylate
(ethyl 3-aminobenzoate methanesulfonate; Sigma-Aldrich).
A rendered Z-stack, at 80 mm thickness each, was taken with
a Zeiss LSM 510 AxioImager.M1 confocal microscope using an
Achroplan 40 /0.8 W objective with an argon laser (488 nm) and
a helium-neon laser (543 nm).
Morpholino design, resuspension and microinjection
A splice-modifying antisense morpholino oligonucleotide
against hmgcrb pre-mRNA (hmgcrb MO), a translation blocking
morpholino oligonucleotide targeting the AUG initiation site of
Fig. 1. Pharmacological inhibition of the HMGCR pathway induces cerebral-
vascular defects in developing zebraﬁsh. (A) Representative schematic diagram
of a 28 hpf zebraﬁsh embryo, with the blue boxed area denoting the forebrain and
the pink boxed area showing the midbrain regions. Scale bar¼200 mm. ((B)–(G))
Representative photomicrographs of Tg(ﬂi1:EGFP);(gata-1:DsRed) embryos soaked
in DMSO or 0.5 mg/L ATV and imaged at 28 hpf. Abbreviations: PMBC, primordial
midbrain channel; MCeV, middle cerebral vein; PPrA, primitive prosencephalic
artery. White arrows indicate the abnormally dilated vessels in the forebrain and
midbrain, whereas the black arrow denotes area of stagnant erythrocyte accumu-
lation in the head. Scale bar¼40 mm.
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pggt1b pre-mRNA (pggt1b MO), and a standard control morpho-
lino against a splice targeting the human b-globin pre-mRNA
(control MO), were obtained from GeneTools (Philomath, OR,
USA). The sequences for the morpholinos used are:
(50-AACTGCATTCATAAACTCACCCAGT-30) (hmgcrb-splice MO);
(50-GCCTGAAGAGACGCGACAGCATCAT 30) (hmgcrb-ATG MO); (50-
CACGCGGTGTGTGGACTCACGGTCA-30) (pggt1b-splice MO); and
(50-CCTCTTACCTCAGTTACAATTTATA-30) (control MO).
All morpholino oligonucleotides were diluted in Danieau
buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM
Ca(NO3)2, 5.0 mM HEPES, pH 7.6) to a ﬁnal concentration of
0.2 mM. The embryos were positioned in individual wells placed
on a plate containing 1.0% agarose. The morpholino solution was
then injected at quantities ranging from 0.5 to 10 ng into 1 to 2
cell-stage embryos through the cell-yolk boundary.
Microangiography
Brieﬂy, 50–56 hpf embryos were anesthetized in tricaine
mesylate (Sigma-Aldrich) and injected intra-vascularly with red
ﬂuorescent microspheres of 0.4 mm diameter (Thermo Scientiﬁc)
through the sinus venosus and/or common cardinal vein. Fluor-
escence micrographs were acquired during a series of observa-
tions under the Nikon NBZ 1500 dissecting microscope, which
was equipped with a standard dsRED ﬁlter set using a Nikon DXM
1200 C digital camera.
DAF-2DA staining
DAF-2DA (4-amino-5-methylamino-20-70-diﬂuoro-ﬂuorescein
diacetate; Calbiochem) staining was performed as previously
described (Lou et al., 2011), with reduced incubation time.
In brief, live embryos were incubated in 10 mM DAF-2DA (in
embryo medium, pH 7.0) and incubated for 5 h in the dark at
28.5 1C, after which ﬂuorescence micrographs were acquired
under the Nikon NBZ 1500 dissecting microscope, which was
equipped with a standard GFP ﬁlter set, using a Nikon DXM
1200 C digital camera.
RNA extraction, RT-PCR and sequencing
Total RNA was harvested from a pool of embryos using TRIzol
reagent (Invitrogen). The RNA was DNase-treated using the
Deoxyribonuclease kit (Invitrogen) to minimize genomic DNA
contamination. cDNA was synthesized from equal concentrations
of RNA using a 1st Strand cDNA Synthesis Kit and M-MLV RT
(Invitrogen) and used as a template in RT-PCR. PCR products were
run on 1.75% agarose gels. Band intensities were quantiﬁed using
ImageJ software. The primers used for PCR analysis were:
(50-CAAACATGGGCTGGTTCAAG-30) (Elf1a forward) and (50-AG
TGGTTACATTGGCAGGG-30) (Elf1a reverse).
The efﬁciency of the hmgcrb splice MO was assessed using
primers ﬂanking exon 3:
(50-CCGTGACAATGTGCCTAATG-30) (hmgcrb forward) and
(50-CAGATCAATCAGCAGCAGGA-30) (hmgcrb reverse).
The efﬁciency of the pggt1b splice MO was assessed using
primers ﬂanking exon 2:
(50-TCTTCTGCCGGTCCATCC-30) (pggt1b forward) and (50-GC
GGTAGTGAGCGGTGAT-30) (pggt1b reverse).
The PCR products were ﬁrst separated by electrophoresis then
excised from the gel and puriﬁed using the Qiagen gel puriﬁcation
kit (Qiagen), according to the manufacturer’s instructions.
Sequencing was performed to verify hmgcrb MO-induced splicing
using the CEQ-8000 Genetic Analysis System and the aforemen-
tioned set of primers.Results
Pharmacological inhibition of the HMGCR pathway leads to cerebral-
vascular defects in developing zebraﬁsh
Sequence alignment of the partial catalytic sites of the HMGCR
proteins revealed that the statin-binding residues (Istvan and
Deisenhofer, 2001) are conserved in both zebraﬁsh HMGCR para-
logs (data not shown), which suggests functional conservation. We
ﬁrst used the Tg(ﬂi1:EGFP;Gata-1:dsRED) line for the simultaneous
visualization of the vascular network and the circulating erythro-
cytes during development. Treatment of these embryos with
0.5 mg/L ATV in embryo medium, starting at 1–2 hpf, in a single-
exposure manner, did not affect the vascular patterning or mor-
phology during 15–25 somite stage (data not shown). However, by
28 hpf, ATV treatment resulted in grossly dilated and diffusely
shaped primitive cerebral-vessels of the forebrain and midbrain
(Fig. 1(A–E) and Fig. S1(A–D) in supplementary material), in
addition to the abnormal conﬁnement of stagnant dsRED-positive
erythrocytes and an attenuated circulation in the cerebral region
(Fig. 1F and G). These observations are indicative of impaired vessel
wall function as the primary cause for the extravasation of
erythrocytes at subsequent stages of development. Moreover, in
these embryos the initial patterning of blood vessels was normal
and no vascular regression or abnormal vessel patterning was
observed, despite the presence of severely distended and blood-
ﬁlled vessels becoming evident as early as 26 hpf (Fig. S2A–F in
supplementary material). Furthermore, the trunk vasculature and
the formation of the segmental arteries were unaffected in these
embryos, reﬂecting the cerebral-vascular speciﬁc nature of these
effects at the doses of statins used (data not shown).
By 33 hpf, cerebral hemorrhage was evident in 46% of
embryos (137/298). The locality and severity of the phenotype
Fig. 2. Pharmacological inhibition of the HMGCR pathway induces cerebral hemorrhage in developing zebraﬁsh. ((A)–(D)) Photomicrographs of embryos soaked in 0.5 mg/L ATV
and imaged at 33 hpf. Black arrows denote areas of hemorrhage. Scale bar¼200 mm. ((E) and (F)) Bright-ﬁeld images of zebraﬁsh embryos soaked in DMSO or 0.5 mg/L ATV,
stained with o-Dianisidine (OD) and imaged at 48 hpf. Black arrows indicate sites where abnormal accumulation of hemoglobinized blood was detected in the brain. The blue
arrow denotes OD-positive cells in the pericardium, the green arrow shows the sinus venosus and the red arrow designates the tail region. Scale bar¼200 mm. ((G) and (H))
Transverse sections through embryo heads at 48 hpf stained with OD. Abbreviations: te, tectum; tel, telencephalon. Scale bar¼200 mm. (I) Percentage of embryos treated with
various doses of ATV and scored for the presence of cerebral hemorrhage at 48 hpf. Numbers above the bars represent the ratios used to calculate the percentages.
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the hemorrhages (Fig. 2A–D). At 48 hpf, the extent of hematoma was
evaluated with o-Dianisidine (OD), a sensitive marker of hemoglobin,
which revealed extensive hemorrhaging in the forebrain, midbrain
and the ventricular zone, along with appreciable reductions in the
abundance of circulating erythrocytes in the pericardium, the sinus
venosus and the tail region (Fig. 2E and F). Cross sections of embryos
stained with OD at 48 hpf revealed hematomas predominantly in the
telencephalon and tectum (Fig. 2G and H). The incidence of hemor-
rhages increased in a dose-dependent manner for ATV treatments
(Fig. 2I). These embryos eventually resolved the hemorrhages and
resumed normal development (Fig. S3A–H in supplementary
material).
To conﬁrm the vascular speciﬁcity of these defects, we per-
formed confocal microscopy at 48–52 hpf on Tg(ﬂi1:EGFP);(gata-
1:DsRed) embryos, which revealed progressive leakage of erythro-
cytes from the prosencephalic artery (PrA) in ATV-treated embryos,
and, when compared with the fully functional PrA observed in
DMSO-treated embryos, the PrA in ATV-treated embryos supported
only sluggish circulation (Fig. 3A–D). Taken together, this conﬁrms
that the blood-ﬁlled and vastly enlarged nascent cranial vessels
observed at 26–28 hpf (Fig. 1A–G), are prone to leakiness and
rupture at subsequent stages of development.
Loss of vascular integrity in the brain was further substantiated
using ﬂuorescence microangiography, which revealed that unlike the
fully lumenized brain vasculature in DMSO-treated embryos (judged
by the retention of the ﬂuorescent microspheres in these vessels),
ATV-treated embryos appeared to have less lumenization and also
exhibited a general tendency to extravasate the injected micro-
spheres at the sites of hemorrhage (Fig. 3E and F), hence further
attesting to the loss of vascular stability in the brain. We next sought
to assess the smooth muscle cell coverage in these embryos using
DAF-2 DA (4-amino-5-methylamino-20-70-diﬂuoro-ﬂuorescein diace-
tate; CALBIOCHEM), a membrane-permeable compound that reacts
with nitric oxide (NO) to form the ﬂuorescent DAF-2T, which is a
marker for functional smooth muscle cell coverage in zebraﬁsh (Zenget al., 2009; Lou et al., 2011). However, no vascular smooth muscle
cell coverage was detected in the brain or trunk during the early
stages of normal zebraﬁsh development (data not shown), which
suggests that nascent vessels are more prone to statin-induced
hemorrhage, partly, by virtue of inadequate coverage with smooth
muscle support. This observation is consistent with molecular and
genetic evidence suggesting that the expression of early vascular
smooth muscle cell markers in zebraﬁsh are not detectable before the
larval stage (Santoro et al., 2009; Seiler et al., 2010).
We also exposed embryos at 1–2 hpf to Cerivastatin (CVT), a
structurally different statin molecule with a comparable afﬁnity
for HMGCR (Istvan and Deisenhofer, 2001). Waterborne exposure
to CVT (0.15 mg/L), in a single exposure manner, resulted in 58%
of embryos having cerebral hemorrhage by 33 hpf (108/174),
which is a phenocopy of the ATV-treatment. To further test the
speciﬁc nature of the pharmacological treatments, a metabolite
rescue experiment was conducted using mevalonate, the immedi-
ate product of the HMGCR-catalysed reaction and a precursor of
both cholesterol and isoprenoids. Treatment of 1-cell stage
embryos with ATV (0.5 mg/L) in the presence of mevalonate
(3.2 mmol/L) were sufﬁcient to rescue the hemorrhage phenotype,
as none of these embryos exhibited apparent hemorrhages (0/121).
In contrast, 53% of the embryos treated with ATV (0.5 mg/L) in the
presence of DMSO showed cerebral hemorrhage by 48 hpf (59/112).
Treatment with mevalonate alone did not induce any overt devel-
opmental defects. The ability of mevalonate to rescue the phenotype
suggests that deﬁciencies in one or more of the metabolites down-
stream of mevalonate within the HMGCR pathway may be impli-
cated in the emergence of the hemorrhage phenotype.
Morpholino-mediated depletion of hmgcrb expression leads to
cerebral-vascular defects in developing zebraﬁsh
Zebraﬁsh possess two paralogous genes encoding an HMGCR
protein. The hmgcrb transcripts are maternally-enriched and exhibit
a ubiquitous expression pattern throughout early embryogenesis,
Fig. 3. Pharmacological inhibition of the HMGCR pathway results in loss of vascular stability and induces vessel rupture. ((A) and (B)) Representative bright-ﬁeld
micrographs of 48–52 hpf Tg(ﬂi1:EGFP);(gata-1:DsRed) embryos treated with DMSO or 0.5 mg/L ATV. The boxed region shows where hemorrhage is observed. Scale
bar¼200 mm. ((C) and (D)) Representative composite confocal Z-stack projections of the boxed regions in the same Tg(ﬂi1:EGFP);(gata-1:DsRed) embryos. Abbreviations:
PrA, prosencephalic artery. Scale bar¼40 mm. ((E) and (F)) Representative photomicrographs of 48–52 hpf embryos treated with DMSO or 0.5 mg/L ATV and subjected to
ﬂuorescence microangiography by intravascular injection of red-ﬂuorescent microspheres. The white arrow shows the site of microsphere extravasation.
Fig. 4. MO-mediated inhibition of the HMGCR pathway phenocopies ATV-treatment. (A) Partial hmgcrb pre-mRNA structure (not to scale) showing the exons (boxes),
introns (black lines), the target of hmgcrb MO (red vertical arrow) and the positions of forward and reverse primers (black arrows) used to test the efﬁciency of the hmgcrb
MO. ((B) and (C)) Representative bright-ﬁeld micrographs of 48 hpf embryos injected with hmgcrb MO and control MO, stained with OD. Black arrows indicate sites of
hemorrhage and blue arrow denotes the sinus venosus. Anterior is to the left and dorsal to the top. Scale bar¼200 mm. (D) RT-PCR analysis of hmgcrb mRNA in hmgcrb
morphant and control MO-injected embryos at 48 hpf. MO injection results in the dose-dependent appearance of a band corresponding to a transcript lacking exon-3.
Doses of ATV are indicated above each lane.
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the liver and the anterior intestine (Thorpe et al., 2004). To
substantiate the phenotypic speciﬁcity of the statin-induced
cranial vascular defects, we induced a transient loss of hmgcrb
gene function with a morpholino oligonucleotide (MO) designed
to hybridize with the third exon-intron boundary of the hmgcrb
pre-mRNA (Fig. 4A). The injection of 2 ng of this hmgcrb MO
resulted in approximately 45% (91/203) of the embryos displaying
cerebral hemorrhage at 48 hpf along with reduced abundance of
erythrocytes in the pericardium and the sinus venosus as
detected by whole-mount OD staining (Fig. 4B and C). The
morphants demonstrated no other overt developmental defects
and eventually recovered from the initial hemorrhage, further
indicating that the impaired HMGCR pathway only affects
cerebral-vascular development during a critical period when
nascent vessels in the brain are more prone to rupture. This
suggests that hmgcrb expression is dispensable in more mature
vessels. Injection of higher quantities of the hmgcrb MO (48 ng)
resulted in developmental arrest, defective angiogenesis in the
trunk, lack of circulation and occasional pericardial edema, and
most of these embryos lacked the cranial hemorrhage phenotype
(data not shown). The efﬁciency of the genetic ablation of hmgcrb
expression was tested at 48 hpf by RT-PCR (Fig. 4D) and sequen-
cing (data not shown) using primers spanning the third exon–
intron boundary. As with the statin-treatment, the exogenous
supplementation of these embryos with mevalonate nearly com-
pletely rescued the splice MO-induced vascular defects at 48 hpf,
with only 2.2% of the morpholino-injected embryos (2 ng) bathed
in mevalonate (4.4 mmol/L) showing cerebral vascular defects (7/
318) at 48 hpf. A second MO directed against the AUG translation-
start site also mirrored the statin-induced hemorrhaging (data
not shown). Overall, these observations further support an essen-
tial role for HMGCR-mediated lipid metabolism in cerebral-
vascular morphogenesis.A deﬁciency in GGPP biosynthesis and impaired GGTase I-facilitated
prenylation of Rho GTPases leads to cerebral-vascular defects in
developing zebraﬁsh
We next tested the hypothesis that statin-induced defects in
vascular stability were attributable to perturbations in GGPP
biosynthesis. To test this hypothesis, 1-cell stage embryos were
treated with ATV (0.5 mg/L) in the presence of geranylgeranyl-
pyrophosphate (GGPP, 4 mg/L) or the vehicle (DMSO:methanol;
50:50, v/v), starting at 1–2 hpf. The addition of GGPP effectively
rescued the hemorrhage phenotype, and by 48 hpf approximately
7% of the embryos co-administered with ATV and GGPP showed
evident cerebral hemorrhages (9/131), compared with 56% of
control embryos receiving ATV and the vehicle (80/143). The
near-complete rescue of the vascular phenotype with GGPP
supplementation suggests a requirement for prenylation in the
establishment of developmental cerebral-vascular stability. To
further demonstrate that decreased GGPP bioavailability under-
lies these cerebral-vascular defects, we selectively targeted the
prenylation pathway. Prenylation of small GTPases, such as Rac1,
RhoA and cdc42, is catalyzed by the cytosolic isoprenyl transfer-
ase, geranylgeranyl pyrophosphate I (GGTase I) (Peterson et al.,
2006; Roberts et al., 2008). The enzyme, GGTase I, catalyzes the
transfer and binding of the 20-carbon geranylgeranyl isoprenoid
to the cysteine-residue of the CAAX motif at the C-terminus of
target Rho GTPases (Fig. 5A).This coupling constitutes a critical
step for the translocation of the Rho GTPases to the plasma
membrane and interaction with other lipophilic proteins.
To speciﬁcally impair this pathway, we injected a splice-
blocking morpholino targeting the second exon-intron boundary
of the pggt1b pre-mRNA, which encodes the b-subunit of GGTase I
(Fig. 5B). Injection of 2.5 ng of the pggt1b MO in 1-cell stage
embryos resulted in 23% of the embryos showing cerebral hemor-
rhage by 48 hpf (49/213) (Fig. 5C and D), thus phenocopying, both
Fig. 5. MO-mediated ablation of pggt1b mimics statin and hmgcrb MO-induced cerebral hemorrhages and effectively reduces the wild-type pggt1b mRNA. (A) Schematic
representation of GGTase I-mediated transfer of a 20-carbon geranylgeranyl lipid to the cysteine residue of Rho GTPases. (B) Partial pggt1b pre-mRNA structure (not to scale)
showing the exons (boxes), introns (black lines), the target of pggt1b MO (red vertical arrow) and the positions of forward and reverse primers (black arrows) used to test the
efﬁciency of the pggt1bMO. ((C) and (D)) Representative bright-ﬁeld photomicrographs of 48 hpf embryos. The blue arrow denotes the site of blood extravasation in the midbrain
region of the embryo injected with pggt1b MO. Anterior is to the left and dorsal to the top. Scale bar¼200 mm. (E) RT-PCR on total RNA extracted from in uninjected and MO-
injected embryos at 48 hpf to assess pggt1b mRNA levels. MO injection results in the loss of wild-type pggt1b mRNA (see text for details). (F) The transcript levels of eif1a were
assessed as an internal control and appeared unchanged.
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with the inhibition of HMGCR. Injection of higher doses of pggt1b
MO (6 ng) only slightly increased the frequency of hemorrhages
(28%, 51/180), but most of these embryos were developmentally
delayed (data not shown). The efﬁcacy of the pggt1bMO was tested
by RT-PCR on total RNA harvested from 48 hpf embryos that were
previously injected with 2.5 ng MO, and showed a near complete
depletion of wild-type pggt1b transcripts (Fig. 5E and F). The
transcript levels of eif1a were assessed as an internal control
(Fig. 5F) and did not show major changes. Based on sequence
analysis, we predicted that MO-induced alternative splicing of
pggt1b exon 2 would result in a frame-shift, thereby introducing a
premature termination codon (TAA) in exon-3, thus targeting this
mRNA for nonsense-mediated decay.
These results support that depletion of the HMGCR pathway
impairs cerebral-vascular stability due to reduced GGPP biosynth-
esis and the consequential decrease in the prenylation status and
membrane targeting of CAAX proteins, which serve as substrates
for GGTase I.
The molecular nature of these statin-induced vascular defects
were further characterized by the use of the Tg(ﬂi1:EGFP-cdc42wt)y48
line in which the expression of EGFP-cdc42 fusion protein shows a
perivacuolar co-localization restricted to the endothelial cells
(Kamei et al., 2006). The protein cdc42, a RhoA GTPase, is implicated
in the regulation of vacuole formation, lumenization and mediation
of endothelial barrier function (Kouklis et al., 2003; Broman et al.,
2006; Ramchandran et al., 2008; Spindler et al., 2010) and it requires
geranylgeranylation, downstream of HMGCR pathway, for its activa-
tion (Peterson et al., 2006; Roberts et al., 2008). Treatment of
Tg(ﬂi1:EGFFP-cdc42wt)y48 embryos with ATV at the 1-cell stage led
to a noticeable reduction in intra-endothelial expression of EGFP-
cdc42 in the brain and the trunk as early as 24 hpf (data not shown).
The decline in vascular-speciﬁc EGFP-cdc42 expression was also
clearly evident in the head and trunk vasculature of these embryos
at 48 hpf (Fig. 6A and B), the stage when cerebral hemorrhage wasmost preponderant in statin-treated embryos. The attenuated EGFP-
cdc42 expression was further validated by measuring EGFP signal
intensity using ImageJ software (Fig. 6E and F). We further estab-
lished that the reduction in ﬂuorescence intensity was not attribu-
table to global developmental defects, vascular regression or
defective angiogenesis resulting from a down-regulation of the ﬂi
promoter in Tg(ﬂi1:EGFP-cdc42wt)y48, since the expression of
ﬂi1:EGFP was unaffected in response to statin treatment and the
brain and trunk vessel morphology and segmental artery formation
was unaltered (Fig. 6C and D). Similarly, quantiﬁcation of the EGFP
signal intensity in these ﬁsh conﬁrmed unaltered expression of
ﬂi1:EGFP protein in the head or trunk vessels (Fig. 6G and H).
Together, these data reﬂect a speciﬁc reduction in cdc42 levels as a
consequence of statin treatment. To investigate the localization of
cdc42 in response to statin exposure, we performed confocal
microscopy on 48–52 hpf Tg(ﬂi1:EGFP-cdc42wt)y48 embryos. We
focused our attention on ISVs due to the ease of imaging. Whereas
the EGFP-cdc42 expression in DMSO-treated embryos exhibited
perivacular localization, outlining the boundaries of the intercellular
lumen in the ISVs, ATV-treated embryos had reduced EGFP-cdc42
expression in the ISVs and any expression was concentrated
primarily at the base of the ISVs (Fig. 6I and J). Taken together,
our evidence suggests that the endothelial-speciﬁc expression of
cdc42 is markedly reduced concomitant with the onset and expan-
sion of hematoma in the brain.Discussion
Through a combination of pharmacological blockers, metabo-
lite rescue and genetic approaches, this study demonstrates that a
transient disruption in the HMGCR pathway induces intracranial
hemorrhaging in zebraﬁsh at a predictable developmental stage.
This cerebral vascular-speciﬁc phenotype was not associated with
any other developmental abnormalities. Of particular clinical
Fig. 6. Inhibition of the HMGCR pathway abolishes the intra-endothelial expression of cdc42. ((A) and (B)) Representative photomicrographs of Tg(ﬂi1:EGFP-cdc42wt)y48
embryos treated with DMSO or 1.0 mg/L of ATV and imaged at 48–52 hpf. ((C) and (D)) Representative photomicrographs of Tg(ﬂi1:EGFP) embryos treated with DMSO or
1.0 mg/L of ATV and imaged at 48–52 hpf. Anterior is to the left and dorsal to the top. Scale bar¼200 mm. ((E)–(H)) Graphs plotting relative EGFP signal intensities in the
head and trunk vasculature (as denoted by the dotted white boxes in (A)–(D)) of (ﬂi1:EGFP-cdc42wt)y48 and Tg(ﬂi1:EGFP) embryos treated with DMSO or 0.5 mg/L of ATV.
Data are presented as the mean and standard error of the mean. N¼15 embryos, t-test, po0.001 (for (E) and (F)). ((I) and (J)) Representative composite confocal Z-stack
projections of the trunk region of Tg(ﬂi1:EGFP-cdc42wt)y48 embryos, showing the localization of EGFP-cdc42 in a single intersegmental artery (ISV). The green arrow
denotes perivacuolar expression of EGFP-cdc42. Scale bar¼40 mm. Anterior is to the left and dorsal to the top.
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logical features that closely resemble CCM pathologies in humans
and mice, such as abnormally dilated and blood-ﬁlled cranial
microvessels prior to the onset of extravasation, intracranial
hemorrhaging and expansion of hematoma, along with evidence
of thrombosis in the vicinity of the lesions. It is likely that
inhibition of the HMGCR pathway perturbs signalling processes
that mitigate the assemblage of angioblasts into nascent vascular
tubes, thus making them more prone to rupture and leakage.
Interestingly, the extravasation of blood components is only
detected in the head, implying that the vessels in this region are
more fragile at this developmental period, hence more easily
ruptured. Since the onset of hemorrhage and the expansion of
hematoma correspond to a period of rapid angiogenesis during
which numerous newly formed blood vessels invade the brain
(Isogai et al., 2001), it is plausible that these nascent vessels that
carry blood for the ﬁrst time would lack adequate coverage with
support cells, making them weak and prone to rupture. Consistent
with this, DAF-2DA staining showed no positive signal for smooth
muscle cells in the brain or trunk vasculature during early
development consistent with previous studies (Santoro et al.,
2009), which suggests that inadequate endothelial contact with
support cells can predispose these early vessels to statin-induced
hemorrhage. We have shown, by ﬂuorescence microangiography,
that defects in the establishment of endothelial cell-to-cell
associations contribute to the loss of vascular stability in these
embryos (Fig. 3E and F). Consistent with this assertion, zebraﬁsh
deﬁcient in VE-cadherin, an endothelial-speciﬁc adhesion protein
located in cell-to-cell junctions and important for vessel stabiliza-
tion, exhibit cerebral-vascular fragility and hemorrhaging at 48 hpf
in zebraﬁsh (Montero-Balaguer et al., 2009).At higher doses (5–10 mg/L), we observed that statin treatment
signiﬁcantly inhibited angiogenic processes in the trunk, as evi-
denced by the incomplete or defective anterior to posterior sprout-
ing of intersegmental vessels (ISV) emanating from the dorsal aorta
(DA), thereby severely restricting circulation in the ﬁsh, and often
resulting in pericardial edema (data not shown), with almost no
cerebral hemorrhages observed. This leads us to speculate that at
higher doses, statin-treatment affects endothelial survival and
migration, whereas at lower doses, vascular stability in the brain
is compromised, to which the hemorrhage phenotype attests. This
is also conﬁrmed through our reverse genetics approach, with high
doses of hmgcrb MO inducing defective angiogenesis in the trunk.
It is intriguing that the temporal and spatial distribution of the
vascular defects reported here are similar to those associated with
the bbh and rhd mutations which were previously characterized in
zebraﬁsh (Buchner et al., 2007; Liu et al., 2007). These ﬁsh were
reported to have hypomorphic mutations in the pak2a and bpixA
genes that encode for proteins involved in regulating the activity
and mediating the function of the Rho GTPases, Rac and cdc42
(Buchner et al., 2007; Liu et al., 2007). The disruption of vascular
permeability in these embryos is consistent with the roles of Rac
and Cdc42 in the maintenance and stabilization of endothelial
barrier function (Spindler et al., 2010). The similar nature of the
hemorrhages described in zebraﬁsh deﬁcient in pak2a and bpixA
and those we report here suggests a molecular interaction between
the HMGCR pathway and Rho GTPase signalling in the regulation of
developmental vascular stability. This is further supported by the fact
that both Rac and cdc42 are natural substrates for the b-subunit
of GGTase I, which facilitates their post-translational modiﬁcation by
the addition of a mevalonate-derived geranylgeranyl lipid, a critical
step required for the activation of these Rho GTPases (Peterson et al.,
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cdc42wt)y48 line in which cdc42 protein is over-expressed in an
endothelial-speciﬁc manner, we observed a decrease in the expres-
sion of EGFP-cdc42 in the cerebral and trunk vessels upon treatment
with statins. This decrease was evident as early as 24 hpf and
persisted to the onset of hemorrhage. We showed that the reduction
in ﬂuorescence intensity was not attributable to global developmental
defects or down-regulation of ﬂi1 promoter activity, since examina-
tion of Tg(ﬂi1:eGFP) embryos showed no apparent alterations in
ﬂuorescence intensity nor signs of defects in cranial or segmental
angiogenesis. Collectively, this observation is suggestive of statin-
induced degradation of cdc42 expression in the vasculature, and it
further this highlights in vivo how alterations of HMGCR activity can
exert effects on the cellular dynamics of cdc42 expression. On the
whole, the rescue of statin-induced hemorrhages by the addition of
GGPP, along with the hemorrhage phenotype elicited by the disrup-
tion of GGTase I-mediated prenylation in zebraﬁsh strongly highlight
a requirement for HMGCR activity for the stabilization of nascent
vessels during early angiogenesis. These data contrast, however with
previous ﬁndings in mice. More speciﬁcally, in mice, the defective
endothelial stability underlying CCM pathogenesis, thought to be
mediated by RhoA hyperactivation, is greatly attenuated upon
pharmacological ablation of the HMGCR pathway, possibly due to
non-cholesterol dependent processes (Whitehead et al., 2009). This
raises the possibility that modulation of HMGCR activity could be a
therapeutic strategy to ameliorate CCM pathobiology (Li and
Whitehead, 2010). More recently using a separate murine model of
CCM, a more speciﬁc pharmacological inhibition of RhoA activity,
through direct targeting of the Rho kinase signalling pathway, was
shown to be similarly effective in signiﬁcantly reducing CCM genesis
(McDonald et al., 2012).
The hemorrhage phenotype described here does not induce
lethality, as these embryos eventually resolve the brief disruption
in vascular stability and resume normal development. This is in
contrast with the embryonic lethality observed in mouse models
of intracranial hemorrhage. Furthermore, the robust and sponta-
neous nature of the vascular phenotype described here, coupled
with the early onset of hemorrhage, the rapid expansion of
hematoma and the optical transparency and accessibility of all
of these processes, aided by the presence of tissue-speciﬁc
transgenic lines and the possibility for high resolution imaging,
make this model applicable for elucidating the pathophysiology of
CCM-like lesions at various stages of progression.Acknowledgements
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